Axiom

Executive Summary

Axiom is a San Francisco-based biotechnology company leveraging mechanistic AI and human-relevant experimental data to predict drug toxicity early in the discovery process. Its platform integrates proprietary lab data with clinical outcomes, aiming to reduce costly late-stage drug failures. By providing scientists with AI-powered clinical risk assessments during early discovery, Axiom seeks to enhance the safety profile of new medicines. Founded in 2015, the company has reached Phase 3 stage, indicating advanced development and potential near-commercial readiness. Axiom's approach addresses a critical pain point in drug development, where toxicity-related failures account for significant attrition. With a focus on safer medicines, the company is positioned to partner with pharmaceutical firms seeking to de-risk their pipelines. The conviction score reflects the high potential of its technology but acknowledges the competitive landscape and execution risks.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major Pharmaceutical Company60% success
• Q2 2026Publication of Key Validation Study Results in Peer-Reviewed Journal70% success
• Q4 2026Series B Funding Round Completion50% success